MICHAEL RAYBURN: Open Payments
NPI 1396923520 · ALPHARETTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,316 in 103 payments from 22 companies in 2025. Trend: 2023 $2,138 · 2024 $1,944 · 2025 $2,316
Food & beverage: $2,316
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 24 | $486 |
| AstraZeneca Pharmaceuticals LP | 11 | $244 |
| HARMONY BIOSCIENCES LLC | 5 | $155 |
| GENZYME CORPORATION | 5 | $153 |
| Viatris Specialty LLC | 6 | $142 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $124 |
| Verona Pharma, Inc. | 5 | $105 |
| Axsome Therapeutics, Inc. | 4 | $105 |
| Insmed, Inc. | 4 | $102 |
| Electromed, Inc. | 9 | $99 |
Products named: TRELEGY ELLIPTA, NUCALA, DUPIXENT, WAKIX, YUPELRI, GLASSIA, TEZSPIRE, Ohtuvayre.
Industry payments across GA — which companies pay providers there.
